CD19 and leukemia: Ongoing/unknown status clinical trials explore the potential of the clinical translation of autologous T-cell IVT-mRNA engineered to express CARs against relapsed or refractory CD19+ leukemia and lymphoma (NCT03166878) and CD20+ B-cell malignancies (NCT02315118).